Related Experiment Videos
Drug treatment in precocious puberty
1Department of Pediatrics, University of California, Davis.
Drugs
|May 1, 1991
Summary
Precocious puberty, occurring before age 8 (girls) or 9 (boys), has central and peripheral causes. Gonadotropin-releasing hormone (GnRH) agonists effectively treat central precocious puberty, improving final height predictions.
Area of Science:
- Pediatric Endocrinology
- Reproductive Medicine
- Growth and Development
Background:
- Precocious puberty involves early pubertal onset before age 8 (girls) or 9 (boys).
- It stems from central (hypothalamic-pituitary-gonadal axis) or peripheral causes.
- Early puberty compromises final adult height due to advanced skeletal age.
Purpose of the Study:
- To review the classification and treatment of precocious puberty.
- To evaluate the efficacy of gonadotropin-releasing hormone (GnRH) agonists and other agents.
Main Methods:
- Review of current literature on precocious puberty classification and treatment.
- Analysis of therapeutic outcomes for central and peripheral forms.
Main Results:
- Central precocious puberty (CPP) is effectively treated with long-acting GnRH agonists, showing minimal side effects.
- GnRH agonists are ineffective for peripheral precocious puberty (PPP).
- Agents like androgen antagonists, testolactone, ketoconazole, and medroxyprogesterone acetate show some success in PPP.
Conclusions:
- GnRH agonists improve final height predictions in CPP.
- Further studies are needed to confirm the long-term benefits of treatments on ultimate height.